Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
This study is currently recruiting participants.
Verified February 2011 by National Cancer Center, Korea
Sponsor:
National Cancer Center, Korea
Collaborators:
Asan Medical Center
Severance Hospital
Information provided by:
National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT01300156
First received: February 18, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |